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S U M M A R Y
Background: Interferon-lambda 4 (IFNL4) ss469415590 is a newly discovered polymorphism that could
predict the treatment response in hepatitis C virus (HCV)-infected patients. This meta-analysis was
performed in order to clarify its speciﬁc effect on the treatment response and to compare it with
interleukin 28b (IL28B).
Method: The commonly used literature databases were searched. Meta-analyses were performed with
ﬁxed/random-effects models using Stata 12.0. The sustained virological response (SVR) rate was
summarized using R software. Publication bias was examined through Egger’s test.
Results: A total of seven studies were ﬁnally included in this meta-analysis. IFNL4 ss469415590 was
demonstrated to be associated with SVR (odds ratio (OR) 3.83, 95% conﬁdence interval (CI) 3.22–4.56,
p < 0.001). Asians had a higher likelihood of achieving SVR than Caucasians (OR = 7.36 vs. 3.54). When
stratifying all the patients according to HCV genotype, a signiﬁcant association was observed in HCV
genotype 1 patients (OR 4.5, 95% CI 2.91–6.95, p < 0.001). In HCV genotype 2/3 patients, the favorable TT/
TT genotype patients tended to have a statistically higher SVR rate than the non-TT/TT genotype patients
(84.4% vs. 78.3%, p = 0.058). Compared with IL28B rs12979860 (OR 3.45) and rs8099917 (OR 3.50),
ss469415590 TT/TT genotype patients showed a slightly higher probability of achieving a SVR (OR
3.61 calculated from studies investigating both IFNL4 and rs12979860; OR 4.86 for studies investigating
both IFNL4 and rs8099917). Furthermore, ss469415590 showed a slightly higher predictive value than
rs12979860 using the diagnostic test tool (area under the curve = 0.71 vs. 0.70). IFNL4 was also
correlated with rapid virological response (RVR) (OR 4.35, 95% CI 1.43–13.20, p = 0.01), viral clearance
(OR 0.31, 95% CI 0.24–0.39, p < 0.001), and HCV susceptibility (OR 0.76, 95% CI 0.65–0.89, p = 0.001).
Conclusions: IFNL4 ss469415590 is signiﬁcantly associated with SVR in HCV genotype 1 patients,
irrespective of race; there is a tendency towards an association in HCV genotype 2/3 patients. Comparable
to IL28B, IFNL4 is correlated with natural viral clearance and HCV susceptibility, additionally IFNL4
ss469415590 has a slightly higher predictive performance over IL28B polymorphisms in regard to SVR.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Hepatitis C virus (HCV) is one of the main causes of chronic
hepatitis and it affects around 3% of the world population.1
Following acute HCV infection, as many as 80% of infected patients* Corresponding author.
E-mail address: liyh_binzhou@126.com (Y. Li).
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1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).fail to eradicate the virus spontaneously; these patients then
develop a chronic infection, which may progress to cirrhosis or
even hepatocellular carcinoma (HCC).2
Pegylated-interferon (PEG-IFN) plus ribavirin (RBV) is currently
one of the treatment regimens for chronic hepatitis C patients. It
has been reported that the treatment efﬁcacy might be inﬂuenced
by virus- and host-related factors.3 Previous studies have explicitly
demonstrated that interleukin 28b (IL28B) polymorphisms have an
inﬂuential impact on the HCV treatment response, such as theciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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(RVR), and spontaneous viral clearance.4–6 Speciﬁcally, in patients
infected with HCV genotype 1, those with the IL28B rs12979860 C
allele or rs8099917 T allele have an almost two-fold increased
likelihood of clearing the virus than those with the T allele or G
allele, respectively. This effect has since been extended to genotype
2/3 and even genotype 4 patients.7–9
The mechanism by which IL28B inﬂuences the treatment
outcome remains elusive. One possible explanation is that IL28B, a
type of interferon (IFN-lambda), not only induces antiviral activity
by itself, but also elicits IFN-stimulated genes (ISGs), which also
have antiviral activity against the virus.10 Recently, Prokunina-
Olsson et al. discovered a new dinucleotide variant ss469415590
(rs368234815) that is in disequilibrium linkage with rs12979860.
The polymorphism ss469415590 leads to a frame shift mutation
and thus creates a new gene designated as interferon-lambda 4
(IFNL4); this gene cannot be produced by homozygote individuals
with the IFNL4 TT allele (IFNL4 TT/TT genotype).6 A previously
reported signiﬁcant predictor for SVR–rs12979860–is actually
located in the intron of IFNL4 and is known to be highly linked with
IFNL4 ss469415590. In other words, it might be IFNL4 rather than
IFNL3 that plays a decisive role in the response of HCV to
treatment. Subsequently, Bibert et al. attested that ss469415590
TT/DG but not rs12979860 induces IL28B and interferon-gamma-
inducible protein 10 (IP-10) expression, suggesting TT/DG as the
sole functional variant temporarily.11
Since then, many more studies have focused on the association
of IFNL4 polymorphism with the treatment response in HCV
patients. Several studies have revealed that IFNL4 ss469415590 is
correlated with SVR in genotype 1/4 patients, but not in genotype
2/3 patients.11–13 Meanwhile, the probability of achieving a
virological response has varied in different ethnicities, and
ss469415590 is more strongly correlated with HCV clearance
than rs12979860.6,12,14,15 However, one study reported contra-
dicting results showing that IFNL4 ss469415590 had no added
beneﬁt for SVR prediction compared to rs12979860,16 and another
study reported IFNL4 ss469415590 to show similar predicting
performance to IL28B rs12979860.
Reliable evidence on IFNL4 polymorphism in regard to HCV
susceptibility, virus clearance, and the treatment response remains
scarce, due in part to the different sample sizes and heterogeneity
in HCV patients, treatment regimens, and durations of the
medications used in the different studies. Furthermore, the
inﬂuence of ss469415590 on the treatment response in HCV-2
and HCV-3 patients has been less convincing. Therefore, a meta-
analysis was performed in the present study to comprehensively
appraise the inﬂuence of IFNL4 ss469415590 on the response to
treatment and clearance of HCV, and to better clarify the effect of
IFNL4 ss469415590 on the likelihood of achieving SVR and RVR in
HCV patients. It was also attempted to estimate the predictive
value of IFNL4 polymorphism for SVR in HCV patients receiving
PEG-IFN/RBV and to compare IFNL4 and IL28B in regard to the
predictive value.
2. Materials and methods
2.1. Search strategy
An electronic search was conducted to identify articles
published up until September 13, 2015, in the following databases:
PubMed, Web of Science, Chinese Biomedicine Database, and China
National Knowledge Infrastructure (CNKI). Medical subject head-
ing (MeSH) terms were the priority in setting the strategy. The
following keywords were used: ‘‘IFNL4’’, ‘‘interferon-lamda 4’’ ,
‘‘interferon lambda 4’’, ‘‘interferon-l4’’ or ‘‘IFN-l4’’ or
‘‘ss469415590’’ or ‘‘rs368234815’’. In addition, the referenceslisted in the articles included were screened so as not to miss any
additional eligible studies.
2.2. Criteria for article screening
Studies were included if they met the following criteria: (1)
the article assessed the association between IFNL4 polymor-
phisms and the HCV treatment response or susceptibility; (2) the
treatment response included SVR and/or RVR; (3) the study
design was a case–control study or cohort study; (4) the odds
ratio (OR) with the 95% conﬁdence interval (95% CI) was
reported, or could be calculated using the data available.
Unpublished reports such as conference abstracts were not
included. Articles including patients with hepatitis B virus (HBV)
or HIV co-infection were all excluded. In the case of more than
one study being performed by the same author(s), these were
regarded as independent studies if the two inclusion time
periods did not overlap.
2.3. Data collection
The data were extracted independently by two investigators (YL
and LY). In the case of any disagreement, the other investigators
were consulted until a consensus was reached. The following
information was extracted: ﬁrst author’s name, date of publication,
ethnicity, country, number of patients, treatment regimen,
duration of treatment, mean age, proportion of male patients,
and IFNL4 single nucleotide polymorphism (SNP) genotype
distributions.
2.4. Treatment outcome
The primary treatment outcome of this meta-analysis was SVR
after treatment with PEG-IFN plus RBV, which was deﬁned as
undetectable HCV RNA at 24 weeks after the cessation of
treatment. The secondary treatment outcome was RVR, which
was deﬁned as the eradication of serum HCV RNA at week 4 after
the initiation of PEG-IFN plus RBV.
2.5. Quality assessment
The quality of the studies included in this meta-analysis was
appraised using previously reported tools.17,18 An eight-point
scoring system was created based on details of the clinical
characteristics reported (Supplementary Material, Table S1); a
score of less than 6 points was deemed to indicate a low quality
study.
2.6. Statistical analysis
Correlation of IFNL4 polymorphisms with the HCV treatment
response was estimated through the summary OR and correspond-
ing 95% CI. The overall effect was assessed using the Z-test; results
were considered signiﬁcant if the p-value was less than 0.05. The
heterogeneity of the included articles was evaluated using I2
statistics (heterogeneity was accepted if p > 0.1 and I2  50%). If
the value of the I2 statistic is less than 50% or the p-value is more
than 0.1, the ﬁxed-effects model can be used; otherwise, a random-
effects model should be used. Egger’s test was performed to
examine publication bias. When estimating the OR, the dominant
model (AA: AB + BB, A as the major allele, B as the minor allele) and
the allele model (A vs. B) were used. The overall rate of SVR was
calculated in a way that resembles meta-analysis: each study is
conferred a weight, and the SVR rate of each study is adjusted
according to the weight that the study contributes to the overall
SVR rate.
Figure 1. Flow chart of the article screening process for the meta-analysis.
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(version 12.0) or R (version 3.0.1) software. All tests were two-
sided and p < 0.05 was regarded as statistically signiﬁcant.
3. Results
A ﬂow diagram depicting the screening process, modiﬁed
according to the PRISMA statement, is given in Figure 1.19 After
reading the titles and abstracts, 20 articles were included for full-
text review. Among these, no treatment was involved in three
articles,20–22 the data were not accessible for two articles,23,24 SVR
was not included clearly as the treatment outcome in three
articles,25–27 one article reported the treatment response in liver
recipients after transplantation,28 and one article included HCV/
HIV co-infected patients.29 Additionally, ﬁve studies were con-
ducted by the same group;14,15,30–32 therefore the most recent two
were selected (Nagaoki31 and Ochi14); one of these provided
detailed genotype information and one presented detailed allele
frequencies. After excluding these 13 studies, the remaining seven
articles were included in the meta-analysis, among which six
articles investigated SVR,6,11–13,16,31 three articles investigated
RVR,13,16,31 one study investigated susceptibility,14 and two
studies explored spontaneous clearance.6,11 These articles includ-
ed a total 4480 HCV patients. The quality assessment showed that
only one study scored less than 6 points and was thus categorized
as a low quality study.31 All of the other studies were of high
quality (Supplementary Material, Table S1). The characteristics of
the qualifying articles are summarized in Table 1.
3.1. IFNL4 polymorphisms and the treatment response in HCV
patients
In this meta-analysis, six studies provided detailed information
on genotyping and one article provided only the allele frequency14
in the analysis of the association of IFNL4 polymorphism with SVR.
Among the six studies, 3577 patients were enrolled, including
1705 patients who achieved SVR and 1872 patients who had no
SVR. The favorable IFNL4 genotype (TT/TT) was present in 34.4% of
the 3577 patients. Overall, 65.9% (95% CI 52.9–78.9%) of the TT/TT
genotype patients achieved SVR compared to 36.4% (95% CI 22.8–
50.1%) of the non-TT/TT genotype patients. Asian HCV patients
who had the TT/TT genotype had a higher SVR rate (88.4%, 95% CI
79.8–97.0%) than Caucasian patients (58.4%, 95% CI 42.3–74.6%)
(Table 2).Table 1
Clinical characteristics of the studies included in this meta-analysis
First author Year Race Country Patient trait Inclusion
time
Stattermayer et al.12 2014 Caucasian Austria Treatment-
naı¨ve
2001–2011
Ochi et al.14 2014 Asian Japan NA – 
Nagaoki et al.31 2014 Asian Japan NA – 
Akkarathamrongsin
et al.13
2014 Asian Thai NA 2007–2012
Prokunina-Olsson
et al.6
2013 Caucasian USA NA – 
Bibert et al.11 2013 Caucasian Switzerland NA 2001–2013
Palmieri et al.16 2014 Caucasian Italy Treatment-
naı¨ve
2005–2010
SVR, sustained virological response; NR, non-response; PEG-IFN, pegylated interferon; R
telaprevir.Meanwhile, the TT/TT genotype correlated with a 3.83-fold
increased probability of achieving SVR (95% CI 3.22–4.56,
p < 0.001); moderate heterogeneity existed (I2 = 28.8%, phe-
tero = 0.188) (Table 3, Figure 2A). On subgroup analysis according
to ethnicity, heterogeneity diminished for each race. Results
showed that Asians were more likely to achieve SVR than
Caucasians (Asian, OR 7.36, 95% CI 4.41–12.28, p < 0.001;
Caucasian, OR 3.54, 95% CI 2.94–4.26, p < 0.001).
In the allele model, allele TT still favored SVR (OR 2.23, 95% CI
2.00–2.48, p < 0.001) (Table 3, Figure 2B). Asian patients who
carried the TT allele still had a higher probability of achieving SVR
compared to Caucasian patients with the TT allele (Asian, OR 3.39,
95% CI 2.51–4.56, p < 0.001; Caucasian, OR 2.09, 95% CI 1.86–2.43,
p < 0.001), which is consistent with the aforementioned results
(Table 3).
Next a subgroup analysis was conducted based on HCV
genotype. Five studies investigated HCV genotypeTreatment regime Duration of
treatment
Genotyping
method
SVR/NR,
n/n
 PEG-IFN + RBV GT1/4: 24–72
weeks;
GT2/3: 24 weeks
RT-PCR +
TaqMan
475/279
PEG-IFN-a-2b + RBV 48 weeks Multiplex PCR
followed by the
Invader assay
547/356
PEG-IFN-a-2b + RBV + TVR
for 12 weeks,
PEG-IFN-a-2b and RBV an
additional 12 weeks
24 weeks Invader assay 226/57
 PEG-IFN-a-2a/2b + RBV GT1: 48 weeks;
GT3: 24 weeks
TaqMan
genotyping
177/48
PEG-IFN-a-2b + RBV 48 weeks TaqMan
genotyping
286/950
 PEG-IFN-a-2b + RBV 48 weeks TaqMan 337/203
 PEG-IFN-a-2b or
a-2a + RBV
48 weeks TaqMan 204/335
BV, ribavirin; GT, genotype; PCR, polymerase chain reaction; NA, not available; TVR,
Table 2
Virological response rate in patients carrying different IFNL4 genotypes
SNPs Number of articles included VR/NR Total response rate (95% CI) Response rate in TT/TT
genotype (95% CI)
Response rate in non-TT/TT
genotypes (95% CI)
IFNL4
SVR 6 1705/1872 47.4% (29.6–65.3%) 65.9% (52.9–78.9%) 36.4% (22.8–50.1%)
Race
Asian 2 403/105 79.3% (75.8–82.9%) 88.4% (79.8–97.0%) 56.5% (48.3–64.7%)
Caucasian 4 1302/1767 41.6% (22.4–60.8%) 58.4% (42.3–74.6%) 31.8% (16.9–46.8%)
Genotype
GT1 5 869/805 53.9% (37.8–69.9%) 73.7% (61.9–85.4%) 38.8% (28.7–48.9%)
GT2/3 3 466/108 81.0% (77.7–84.2%) 84.4% (80.3–88.6%) 78.3% (73.5–83.1%)
RVR 3 489/558 55.6% (18.7–92.6%) 68.9% (53.9–83.9%) 36.5% (0–74.6%)
IFNL4, interferon-lambda 4; SNP, single nucleotide polymorphism; VR, virological response; NR, no response; CI, conﬁdence interval; SVR, sustained virological response;
RVR, rapid virological response.
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had a higher SVR rate (73.7%, 95% CI 61.9–85.4%) than non-TT allele
carriers (38.8%, 95% CI 28.7–48.9%) (Table 2). The probability
increased to 4.5-fold (95% CI 2.91–6.95, p < 0.001), which is higher
than the overall effect (OR 3.83) in HCV patients (Table 3;
Supplementary Material, Figure S1). Also, in Asian HCV-1
patients, the probability of achieving SVR was higher than that
in Caucasian HCV-1 patients (OR 9.79 vs. 4.3, respectively).
For genotype 2/3 patients, three studies including 486 SVR
patients and 108 non-SVR patients were assessed. The results
indicated an insigniﬁcant predictive role of IFNL4 TT/TT genotype
for SVR in genotype 2/3 patients (OR 1.43, 95% CI 0.91–2.26,
p = 0.125) (Table 3; Supplementary Material Figure S2) in these
studies.
When analyzing the SVR rate in TT/TT genotype and non-TT/TT
genotype patients, around 84.4% (95% CI 80.3–88.5%) of TT/TT
patients and 78.3% (95% CI 73.5–83.1%) of non-TT/TT patients
achieved SVR (p = 0.058) (Table 2). Additionally, IFNL4
ss469415590 TT/TT genotype was associated with HCV genotype
4 (OR 8.53, 95% CI 3.00–24.26, p < 0.001) and genotype 6 patients
(OR 7.08, 95% CI 2.87–17.45, p < 0.001) (Table 3).
Among all the studies included, three focused on RVR.13,16,31 In
total, 489 patients who had RVR and 558 patients who did not
were included. The results indicated that the IFNL4 TT/TT
genotype was correlated with a 4.35-fold increased likelihood
of achieving RVR (95% CI 1.43–13.20, p < 0.001) (Table 3)
compared with the non-TT/TT genotype when both received
IFN plus RBV.Table 3
Summary of the odds ratio and its 95% conﬁdence interval in the meta-analysis
IFNL4 Number of studies VR/NR OR 95% CI p-Val
SVRc 6 1705/1872 3.83 3.22–4.56 <0.00
Asian 2 403/105 7.36 4.41–12.28 <0.00
Caucasian 4 1302/1767 3.54 2.95–4.26 <0.00
SVR (allele) 5 3698/4246 2.23 2.00–2.48 <0.00
Asian 1 1094/712 3.39 2.51–4.56 <0.00
Caucasian 4 2604/3534 2.09 1.86–2.34 <0.00
Genotypec
GT1 5 869/805 4.5 2.91–6.95 <0.00
Asian 2 273/79 9.79 5.33–17.99 <0.00
Caucasian 3 596/726 3.69 2.81–4.84 <0.00
GT2/3 3 466/108 1.43 0.91–2.26 0.125
GT6 2 98/58 7.08 2.87–17.45 <0.00
GT4 1 65/49 8.53 3.00–24.26 <0.00
RVRc 3 489/558 4.35 1.43–13.20 0.01 
IFNL4, interferon-lambda 4; VR, virological response; NR, no response; OR, odds ratio; C
random-effects model; GT, genotype; RVR, rapid virological response.
a Dominant model.
c p-Value for OR.
b p-Value for heterogeneity.3.2. IFNL4 polymorphisms and HCV susceptibility and spontaneous
clearance
After Prokunina-Olsson et al. reported IFNL4 to be associated
with impaired clearance of HCV,6 several studies replicated this
experiment. Conﬁrmation was obtained that the IFNL4 TT/TT
genotype favored spontaneous clearance (OR 0.31, 95% CI 0.24–
0.39, p < 0.001). Additionally, one study recruited healthy
controls.14 The results showed that the IFNL4 TT/TT genotype
has a protective effect on HCV chronic infection (OR 0.76, 95% CI
0.65–0.89, p = 0.001). The allele model again substantiated these
conclusions (data not shown), which reinforced the association of
IFNL4 polymorphisms with HCV susceptibility.
3.3. IL28B polymorphisms and the HCV treatment response in studies
included in the meta-analysis
IL28B rs12979860 and rs8099917 were the main polymor-
phisms investigated in these studies. In total, ﬁve studies were
included that concurrently focused on the relationship of IL28B
rs12979860 with HCV, 6,11–13,16 and three studies investigated
rs8099917.12,16,31 Consistent with previous studies, rs12979860
and rs8099917 both correlated with SVR in the dominant model
(rs12979860, OR 3.45, 95% CI 2.89–4.11, p < 0.001; rs8099917, OR
3.50, 95% CI 2.02–6.06, p < 0.001). Meanwhile, the overall effect of
IFNL4 polymorphism on SVR was summarized based on the ﬁve
studies that investigated rs12979860 and the three studies that
investigated rs8099917. In the ﬁve studies analyzing rs12979860,ue (OR)a I2 p-Value (Hetero)b Effect model Publication bias
1 28.80% 0.188 F 0.616
1 0.00% 0.381 F
1 0.00% 0.665 F
1 37.00% 0.134 F 0.917
1 – – F
1 0 0.885 F
1 61.30% 0.024 R 0.652
1 0.00% 0.453 F
1 23.60% 0.27 F
 0 0.991 F 0.363
1 0 0.333 F –
1 – – F –
90.40% <0.001 R 0.918
I, conﬁdence interval; SVR, sustained virological response; F, ﬁxed-effects model; R,
Figure 2. Forest plot for the overall odds ratio of IFNL4 with HCV SVR. (A) OR calculated in the dominant model; (B) OR calculated in the allele model. For the forest plot, the
black diamond represents the OR estimate for each study and the size of the gray area reﬂects the weight in the pooled analysis; the horizontal line indicates the 95%
conﬁdence interval; the white diamond represents the pooled OR. (IFNL4, interferon-lambda 4; HCV, hepatitis C virus; SVR, sustained virological response.).
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studies investigating rs8099917, the OR was 4.86 (95% CI 3.05–
7.74, p < 0.001). Both ORs were higher than those for IL28B
polymorphisms.
A diagnostic meta-analysis was then adopted to roughly
evaluate the predictive values for SVR of IFNL4 ss469415590,
rs12979860, and rs8099917. The clinical SVR diagnosis criteria
were set as the gold standard reference. The case number of patients
who carried the favorable genotype (TT/TT for ss469415590, CC for
rs12979860, and TT for rs8099917) and ﬁnally achieved SVR was
regarded as the true-positive value. By the same token, patients
with the non-favorable genotype who achieved SVR were false-
negative, patients with the favorable genotype who did not achieve
SVR were false-positive, and patients with the non-favorable
genotype who did not achieve SVR were true-negative. When the
ﬁve studies that concurrently investigated IFNL4 and rs12979860were analyzed, a slightly larger area under the curve (AUC) was
obtained for IFNL4 ss469415590 (AUC 0.71, 95% CI 0.67–0.75)
(Supplementary Material, Figure S3A) than rs12979860 (AUC 0.70,
95% CI 0.66–0.74) (Supplementary Material, Figure S3B). In the
three studies that investigated both IFNL4 and rs8099917, the AUC
could not be calculated as the number of studies was less than the
number of quadrature points. However, the higher OR for the IFNL4
polymorphism indicated its higher performance in predicting SVR
than IL28B.
3.4. Publication bias and sensitivity analysis
No publication bias was found for any of the studies included in
this meta-analysis (Table 2; Supplementary Material, Figure S4),
which is indicative of the accuracy of the overall effect summarized
through meta-analysis.
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omission of every study. After omitting each study, the overall
effects of IFNL4 on the treatment response and spontaneous viral
clearance did not differ signiﬁcantly (data not shown). Therefore
the results are reliable.
4. Discussion
In this study, it was clearly demonstrated that the IFNL4
ss469415590 (rs368234815) favorable genotype (TT/TT) was
correlated with the HCV treatment response (SVR and RVR),
especially in HCV-1 patients. In addition, IFNL4 polymorphism
might also be associated with spontaneous virus clearance and
chronic HCV susceptibility. Asians had a higher frequency of the
TT/TT genotype than Caucasians, and thus had a higher probability
of achieving SVR when both received standard treatment. IL28B
rs12979860 and rs8099917 were still found to be correlated with
SVR based on these studies, but seemed to have a weaker effect
than IFNL4 ss469415590 in terms of the predictive value in SVR.
As described previously, IFNL4 ss469415590 has recently been
discovered to be located upstream of IFNL3 (IL28B) and is in
linkage disequilibrium with rs12979860.6 Similar to IL28B, IFNL4
ss469415590 has a variable frequency distribution: Asians have a
higher TT/TT genotype frequency than Caucasians. This in turn
could reﬂect the SVR rate in the two different races, with Asians
having a much higher rate than Caucasians. The present meta-
analysis, which summarized the overall effect of IFNL4 in
predicting SVR and also conducted a subgroup analysis based on
race, substantiated this. Therefore, generally speaking, Asians who
are chronically infected with HCV will have better outcomes.
Apart from the treatment response, IFNL4 polymorphism is also
relevant to HCV susceptibility and natural virus clearance, which
paralleled IL28B. Given the minor allele frequency distribution
among the races and in light of the role of human leukocyte antigen
DP/DQ (HLA-DP/DQ) in HBV, which is regarded as the main genetic
factor that contributes to the discrepancy in prevalence world-
wide,33 it may also be concluded that IFNL4 or IL28B exerts such
effects. With the higher favorable allele frequency of IFNL4 or
IL28B in Asians, the prevalence of HCV in Asians is thus much lower
than in the Caucasian population.
In spite of the similarities, disparity also exists between IFNL4
and IL28B. In this study, in addition to the overall effect of IFNL4
and IL28B calculated from the studies included, a comparison was
made of the predictive effects of IFNL4 and IL28B based on the
studies that concurrently investigated the two gene polymor-
phisms to eliminate the potential overestimation of the effects. By
means of a diagnostic meta-analysis, it was clearly indicated that
IFNL4 has a much stronger association with the treatment
response and a higher predictive value for SVR, compared with
IL28B rs12979860. Since the comparison was made in studies that
simultaneously genotyped IFNL4 and IL28B polymorphisms, it was
possible to keep the study population the same and to some extent
eliminate some potential confounders, and the appraisal of the SVR
predictive value was more persuasive. Additionally, in regard to
disparity between IFNL4 and IL28B, some discordance in the
genotypes might exist. In other words, some patients might have
the IL28B rs12979860 major genotype but the IFNL4 minor
genotype. Such patients might still achieve SVR and vice versa.
These patients should be investigated in a future study to
accurately analyze the relationship between IFNL4 and IL28B,
which might be helpful in individualized treatment.
The subgroup analysis stratiﬁed by HCV genotype indicated
that IFNL4 was deﬁnitely correlated with SVR in HCV-1 patients,
with a higher likelihood of SVR in Asian HCV-1 TT/TT genotype
patients than in Caucasian patients. However, from the few
published studies that investigated HCV-2/3 patients separately,no beneﬁcial effect in regard to SVR was observed in IFNL4 TT/TT
genotype patients (p > 0.05). When the SVR rate was analyzed in
TT/TT and non-TT/TT genotype patients, TT/TT patients showed an
obviously higher SVR rate than non-TT/TT genotype patients
(84.4% vs. 78.3%, p = 0.058). Therefore, the IFNL4 TT/TT genotype
still tended to favor SVR in HCV-2/3 patients, although because of
the limited number of studies, this effect did not reach statistical
signiﬁcance. Furthermore, several studies involving HCV-4 and
even HCV-6 patients still indicated that the IFNL4 TT/TT genotype
favored SVR in these two categories of patients. Thus, overall, the
IFNL4 TT/TT genotype favored or at least showed a tendency to
favor SVR for patients with each genotype of HCV.
Of note, another meta-analysis was published during the
submission and revision of this paper.33 Consistent with the
present results, the authors of that meta-analysis showed that
IFNL4 rs368234815 can predict SVR in HCV patients, which is
independent of HCV genotype, patient ethnicity, and treatment
regimen. A considerable number of studies have focused on
this,34,35 and the role of IFNL4 becomes more and more evident.
Although it was clearly found in this study that IFNL4 is
correlated with the HCV treatment response, and it is also
suggested that IFNL4 is slightly superior to IL28B in predicting
SVR, the exact mechanism underlying these phenomena remains
unclear. Bibert et al.11 demonstrated that IFNL4 ss469415590
promotes the methylation of its adjacent cytosine residue, which
remains unmethylated in TT/TT patients. They also showed that
individuals carrying the mutant allele of IFNL4 express lower levels
of IP-10, suggesting that IFNL4 exerts its effect through IP-10 and
might be linked to some ISGs. However, the mechanism of this link
is elusive and warrants exploration in further studies.
Certain other limitations should be stated with regard to this
study. First, only two studies recruited Asian HCV patients
(Japanese and Thai), thus whether the conclusions apply to
patients in other Asian countries, such as China, Korea, etc.,
requires validation in further studies. Second, few studies focused
on RVR, HCV susceptibility, and natural viral clearance, thus
further subgroup analyses were not conducted since the statistical
power would not have been sufﬁcient after stratiﬁcation. Third,
when comparing the magnitude of the association between genetic
factors and the disease state, it would be simpler and more direct to
compare the p-values. However, the diagnostic meta-analysis was
simulated in this study, and the predictive value for the favorable
genotype of each SNP in SVR was compared. This would be more
convincing than the single p-value in regard to appraising the
performance of each SNP for predicting the probability of SVR;
however, the AUC was not drawn for rs8099917 because of the
limited number of studies (three studies). The OR of IFNL4 was still
greater than that of rs8099917, therefore the conclusion could be
drawn that IFNL4 excels in predicting SVR in HCV patients when
receiving standard of care.
Notwithstanding these limitations, this meta-analysis compre-
hensively analyzed the overall effect of IFNL4 polymorphism
ss469415590 on the HCV treatment response for the ﬁrst time. It is
concluded that the IFNL4 ss46941550 TT/TT genotype favors SVR
and natural viral clearance, particularly in Asian patients as well as
in HCV-1 patients. Compared with IL28B polymorphisms
(rs12979860, rs8099917), IFNL4 ss469415590 might have a higher
predictive value for SVR in HCV patients who have received
previous standard of care. However, this study found only a
negative association in HCV-2/3 patients, which might be
attributable to the limited number of studies. Thus more studies
investigating the relevance of IFNL4 with regard to SVR in HCV-2/3
patients are needed. Additionally, since the mechanism underlying
the signiﬁcant correlation of IFNL4 polymorphism with HCV SVR
remains elusive, further studies should focus on this, which might
provide evidence to help cure HCV infections in the future.
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